EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective

Piercarlo Minoretti iD, Enzo Emanuele iD

Medical Sciences · 2026

DOI: 10.3390/medsci14050572 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Sciences, 2026. Verfasst von Piercarlo Minoretti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Drug Repositioning, Immunologic Factors. Die Arbeit nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since 2020, billions of doses of COVID-19 messenger RNA (mRNA) lipid nanoparticle vaccines have been administered worldwide, generating one of the largest pharmacovigilance databases for a modern therapeutic class. Intriguingly, their immunopharmacologic profile—including the engagement of innate nucleic acid sensors, systemic type I interferon signaling, dendritic cell-mediated cross-priming of CD8+ T cells, and upregulation of programmed cell death ligand 1 (PD-L1)—may extend beyond COVID-19 prophylaxis. Retrospective evidence from six independent cohorts, one of which is a multinational health-data network, indicated that vaccination within 100 days of immune checkpoint inhibitor (ICI) initiation may improve survival of patients with malignancies, including in immunologically cold tumors, although a substantial fraction of the original effect may be attributed to pandemic-era selection bias. Here, we examine the mechanistic basis and available evidence for the repurposing of licensed COVID-19 mRNA vaccines as antigen-agnostic immunomodulators. We identified five candidate contexts for prospective evaluation—namely, (1) PD-L1-negative non-small cell lung cancer initiating ICI therapy, (2) perioperative immune dysfunction in major cardiac surgery, (3) chronic hepatitis B, (4) chronic HIV with persistent immune exhaustion, and (5) sepsis-induced immunoparalysis. Methodological foundations for confirmatory assessment—comprising target trial emulation, Mendelian randomization, and pragmatic trial design—are now sufficiently developed to enable implementation. Prospective evaluation of the antigen-agnostic repurposing hypothesis is operationally feasible, albeit constrained by residual confounding and uncertainty about the durability of vaccine-induced innate reprogramming.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesDrug RepositioningImmunologic FactorsHumansSARS-CoV-2mRNA VaccinesRNA, MessengerVaccines, SyntheticPandemics

Stichwörter der Autor:innen

COVID-19 mRNA vaccinesantigen-agnosticimmunomodulationdrug repurposingimmune checkpoint inhibitorstarget trial emulationtrained immunitytype I interferon

Substanzen

COVID-19 VaccinesImmunologic FactorsmRNA VaccinesRNA, MessengerVaccines, Synthetic

Autor:innen und Institutionen

  • Department of Social Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain.
  • Studio Minoretti, I-23848 Oggiono, LC, Italy.
  • 2E Science, I-27038 Robbio, PV, Italy.

ORCID-Profile: Piercarlo Minoretti, Enzo Emanuele

Zitieren

APA

Minoretti, P., & Emanuele, E. (2026). COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective. Medical Sciences. https://doi.org/10.3390/medsci14050572

Vancouver

Minoretti P, Emanuele E. COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective. Medical Sciences. 2026. doi:10.3390/medsci14050572

BibTeX
@article{Minoretti2026,
  author = {Minoretti, Piercarlo and Emanuele, Enzo},
  title = {COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14050572}
}
Kostenlos starten →